基因型引导的抗血小板治疗在缺血性脑血管病中的研究进展
Research Progress of Genotype-Guided Antiplatelet Therapy in Ischemic Cerebrovascular Disease
DOI: 10.12677/acm.2025.151189, PDF,   
作者: 唐洁莉：成都中医药大学临床医学院，四川 成都；陈卫银*：成都中医药大学附属医院神经内科，四川 成都
关键词: 缺血性脑血管疾病；氯吡格雷耐药；基因多态性；抗血小板；Ischemic Cerebrovascular Disease； Clopidogrel Resistance； Gene Polymorphism； Antiplatelet
摘要: 缺血性脑血管疾病(ischemic cerebrovascular disease, ICVD)中一般短暂性脑缺血发作(transient ischemic attack, TIA)和缺血性脑卒中(ischemic stroke, IS)多发，抗血小板治疗是ICVD急性期和二级预防最重要的环节，部分ICVD患者服用氯吡格雷抗血小板过程中存在氯吡格雷耐药。本文就ICVD患者氯吡格雷耐药(clopidogrel resistance, CR)、基因多态性、前瞻性研究及基因检测意义、氯吡格雷抵抗患者抗血小板治疗方案作一综述，以期在临床中为缺血性脑血管疾病病人提供更为科学化、个体化的治疗。
Abstract: Transient ischemic attack and ischemic stroke are common in ischemic cerebrovascular diseases, and antiplatelet therapy is the most important link in the acute phase and secondary prevention of ICVD. Some patients with ICVD have clopidogrel resistance during taking clopidogrel antiplatelet. This article reviews the clopidogrel resistance, gene polymorphism and the significance of genetic testing, prospective study and antiplatelet therapy for patients with clopidogrel resistance in ICVD, in order to provide more scientific and individualized treatment for patients with ischemic cerebrovascular disease in clinic.
文章引用：唐洁莉, 陈卫银. 基因型引导的抗血小板治疗在缺血性脑血管病中的研究进展[J]. 临床医学进展, 2025, 15(1): 1413-1419. https://doi.org/10.12677/acm.2025.151189

参考文献

[1] Alakbarzade, V., Huang, X., Ster, I.C., McEntagart, M. and Pereira, A.C. (2020) High On-Clopidogrel Platelet Reactivity in Ischaemic Stroke or Transient Ischaemic Attack: Systematic Review and Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases, 29, Article ID: 104877. [Google Scholar] [CrossRef] [PubMed]
[2] Scott, S.A., Sangkuhl, K., Gardner, E.E., Stein, C.M., Hulot, J., Johnson, J.A., et al. (2011) Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clinical Pharmacology & Therapeutics, 90, 328-332. [Google Scholar] [CrossRef] [PubMed]
[3] Yi, X., Lin, J., Wang, Y., Zhou, J., Zhou, Q. and Wang, C. (2018) Response to Clopidogrel Is Associated with Early Neurological Deterioration after Acute Ischemic Stroke. Oncotarget, 9, 19900-19910. [Google Scholar] [CrossRef] [PubMed]
[4] 郭秀梅, 林小娟, 吴静, 等. 急性缺血性脑卒中基于CYP2C19基因检测行抗血小板治疗的临床效果[J]. 中国卫生标准管理, 2024, 15(4): 140-143.
[5] Wen, Y., Culhane‐Pera, K.A., Thyagarajan, B., Bishop, J.R., Zierhut, H., Lo, M., et al. (2020) Potential Clinical Relevance of Differences in Allele Frequencies Found within Very Important Pharmacogenes between Hmong and East Asian Populations. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 40, 142-152. [Google Scholar] [CrossRef] [PubMed]
[6] Yan, Y., Hao, R., Zhao, X., Xia, X., Wang, L. and Li, X. (2022) Relationship between CYP2C19*2, *3 Gene Polymorphism and the Recurrence in Ischemic Stroke Patients Treated with Clopidogrel in China: A Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases, 31, Article ID: 106798. [Google Scholar] [CrossRef] [PubMed]
[7] 刘立雄, 张姗姗, 马培, 等. CYP2C19基因多态性与急性缺血性脑卒中氯吡格雷抵抗相关性研究[J]. 黑龙江医药科学, 2023, 46(5): 69-71.
[8] Zhou, Y., Ingelman‐Sundberg, M. and Lauschke, V. (2017) Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐Analysis of Population‐Scale Sequencing Projects. Clinical Pharmacology & Therapeutics, 102, 688-700. [Google Scholar] [CrossRef] [PubMed]
[9] 沙晶, 李红燕. 新疆地区汉族与维吾尔族急性轻型缺血性卒中或短暂性脑缺血发作患者的CYP2C19基因多态性和预后[J]. 中国医药, 2022, 17(4): 522-525.
[10] 周正明, 杨晨, 李红燕. 新疆地区缺血性脑卒中患者中氯吡格雷相关基因CYP2C19的基因多态性研究[J]. 中国临床神经科学, 2022, 30(6): 628-633.
[11] 程龙飞, 许嘉欣, 罗文虹, 等. 潮州地区心脑血管病人群氯吡格雷基因多态性分析[J]. 心血管病防治知识, 2023, 13(24): 16-20.
[12] 曾宏亮, 李彬. CYP2C19基因多态性所致氯吡格雷抵抗与进展性脑梗死的相关性研究[J]. 临床医药实践, 2022, 31(6): 428-431.
[13] Li, P., Cao, M., Liu, L., Chen, L., Liang, S. and Wang, Y. (2024) Analysis of the Effect of CYP2C19 Gene Properties on the Anti-Platelet Aggregation of Clopidogrel after Carotid Artery Stenting under Network Pharmacology. BMC Pharmacology and Toxicology, 25, Article No. 34. [Google Scholar] [CrossRef] [PubMed]
[14] 马梦佳, 赵军, 袁圆. PON1、ABCB1基因多态性在急性轻型脑卒中患者中的分布及其对短期预后的影响[J]. 中国动脉硬化杂志, 2021, 29(3): 247-253.
[15] 卿婷, 易兴阳, 王淳, 等. 氯吡格雷相关基因多态性与缺血性脑卒中早期神经功能恶化的相关性研究[J]. 华西医学, 2022, 37(6): 830-837.
[16] 张云芳, 庄杉杉, 余艳, 等. PEAR1基因多态性与缺血性脑卒中的相关性研究[J]. 昆明医科大学学报, 2023, 44(11): 135-139.
[17] 明敏, 殷佳丽. 江西省赣南地区缺血性脑卒中患者氯吡格雷的药物基因组学研究[J]. 智慧健康, 2022, 8(5): 107-109.
[18] 刘宏达, 邵祥忠, 李林, 等. CYP2C19基因多态性对高危非致残性缺血性脑血管事件患者抗血小板治疗预后的影响[J]. 中南医学科学杂志, 2023, 51(6): 938-941.
[19] 李松良, 梁大桐, 温思, 等. 轻型脑梗死患者CYP2C19基因多态性及抗血小板精准治疗对近期预后的影响[J]. 右江医学, 2024, 52(6): 491-495.
[20] 夏云强, 季雪霞, 杜瑞超, 等. 临床药师基于CYP2C19基因多态性的神经介入支架术后氯吡格雷调整的效果分析[J]. 中国实用医药, 2023, 18(15): 28-32.
[21] 顾大群, 汪洋, 张扬, 等. 调整的抗血小板聚集治疗方案对老年未破裂颅内动脉瘤介入治疗围手术期缺血事件发生的影响分析[J]. 中国脑血管病杂志, 2023, 20(1): 20-26+73.
[22] Minderhoud, C., Otten, L.S., Hilkens, P.H.E., van den Broek, M.P.H. and Harmsze, A.M. (2022) Increased Frequency of CYP2C19 Loss-of-Function Alleles in Clopidogrel‐Treated Patients with Recurrent Cerebral Ischemia. British Journal of Clinical Pharmacology, 88, 3335-3340. [Google Scholar] [CrossRef] [PubMed]
[23] 杨海怡, 练思雅, 蔡世宏, 等. CYP2C19基因指导氯吡格雷个体化治疗缺血性脑卒中有效性和安全性的meta分析[J]. 重庆医学, 2024, 53(9): 1378-1383.
[24] 徐新平, 林晓霖, 罗毅峰, 等. 急性缺血性脑卒中患者双抗治疗中采取药物相关基因检测的临床意义[J]. 中国药物滥用防治杂志, 2024, 30(6): 1042-1044+1052.
[25] Bedair, K.F., Smith, B., Palmer, C.N.A., Doney, A.S.F. and Pearson, E.R. (2023) Pharmacogenetics at Scale in Real-World Bioresources: CYP2C19 and Clopidogrel Outcomes in UK Biobank. Pharmacogenetics and Genomics, 34, 73-82. [Google Scholar] [CrossRef] [PubMed]
[26] Wang, Y., Chen, W., Lin, Y., Meng, X., Chen, G., Wang, Z., et al. (2019) Ticagrelor plus Aspirin versus Clopidogrel plus Aspirin for Platelet Reactivity in Patients with Minor Stroke or Transient Ischaemic Attack: Open Label, Blinded Endpoint, Randomised Controlled Phase II Trial. BMJ, 365, l2211. [Google Scholar] [CrossRef] [PubMed]
[27] Pan, Y., Meng, X., Jin, A., Johnston, S.C., Li, H., Bath, P.M., et al. (2022) Time Course for Benefit and Risk with Ticagrelor and Aspirin in Individuals with Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial. JAMA Neurology, 79, 739-745. [Google Scholar] [CrossRef] [PubMed]
[28] Wang, Y., Meng, X., Wang, A., Xie, X., Pan, Y., Johnston, S.C., et al. (2021) Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. New England Journal of Medicine, 385, 2520-2530. [Google Scholar] [CrossRef] [PubMed]
[29] 王名丽, 陈蕊, 刘晓莉, 等. 高危非致残缺血性脑血管事件抗血小板治疗的研究进展[J]. 临床神经病学杂志, 2024, 37(5): 379-383.
[30] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国缺血性卒中和短暂性脑缺血发作二级预防指南2022 [J]. 中华神经科杂志, 2022, 55(10): 40.
[31] 高欣欣. CYPC19基因指导下的急性非致残性卒中患者抗血小板的研究[D]: [硕士学位论文]. 长春: 吉林大学, 2022.
[32] 李宇, 王怀森, 冯晓俊, 等. 替格瑞洛对比氯吡格雷治疗携带CYP2C19功能缺失等位基因的轻度缺血性卒中或短暂性脑缺血发作患者有效性和安全性的系统评价[J]. 中国现代应用药学, 2024, 41(5): 678-683.
[33] 赖开生, 靳文勋, 江慧, 等. CYP2C19基因多态性在指导抗血小板药物选择治疗中的意义[J]. 河北医学, 2022, 28(8): 1325-1331.
[34] Liu, L., Li, Y. and Li, Y. (2023) Thromboelastographic and Gene Polymorphism Bimodality Detection for Dual Antiplatelet Aggregation Therapy in Individuals with Clopidogrel-Resistant Symptomatic Intracranial Artery Stenosis. Combinatorial Chemistry & High Throughput Screening, 27, 455-461.
[35] 王而强, 田晓旭, 周中和, 等. 急性重症脑梗死应用氯吡格雷治疗效果与CYP2C19基因多态性关系[J]. 临床军医杂志, 2019, 47(12): 1313-1315.
[36] 宋慧群. 氯吡格雷加量治疗CYP2C19中间代谢型症状性脑动脉狭窄患者的临床研究[D]: [硕士学位论文]. 青岛: 青岛大学, 2019.
[37] 秦亚东. 双负荷剂量氯吡格雷联合阿司匹林治疗急性缺血性脑血管病的临床效果[J]. 中国民康医学, 2019, 31(18): 12-14.
[38] 马冬娇, 陈国芳, 冯尧, 等. 强化氯吡格雷对CYP2C19中慢代谢型轻型卒中患者的疗效与安全性[J]. 中国临床研究, 2022, 35(8): 1051-1054.
[39] 朱晓茹, 陈国芳, 时官支, 等. 不同剂量氯吡格雷联合阿司匹林在CYP2C19基因即时检测下对HR-NICE患者的疗效研究[J]. 医学研究杂志, 2023, 52(11): 123-127+208.
[40] 饶世俊, 苏微微, 孙志华, 等. 脑梗死氯吡格雷抵抗病人应用不同剂量与频次氯吡格雷治疗策略的效果比较[J]. 中西医结合心脑血管病杂志, 2021, 19(15): 2644-2647.
[41] 李定远, 于净, 韩若冰, 等. 阿司匹林、氯吡格雷、西洛他唑对缺血性卒中二级预防的疗效性和安全性的网络Meta分析[J]. 沈阳药科大学学报, 2018, 35(8): 680-689+706.
[42] Kim, S.M., Jung, J.M., Kim, B.J., et al. (2019) Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. Stroke, 50, 3503-3511.
[43] Toyoda, K., Uchiyama, S., Yamaguchi, T., Easton, J.D., Kimura, K., Hoshino, H., et al. (2019) Dual Antiplatelet Therapy Using Cilostazol for Secondary Prevention in Patients with High-Risk Ischaemic Stroke in Japan: A Multicentre, Open-Label, Randomised Controlled Trial. The Lancet Neurology, 18, 539-548. [Google Scholar] [CrossRef] [PubMed]
[44] Hoshino, H., Toyoda, K., Omae, K., Ishida, N., Uchiyama, S., Kimura, K., et al. (2021) Dual Antiplatelet Therapy Using Cilostazol with Aspirin or Clopidogrel: Subanalysis of the Csps.com Trial. Stroke, 52, 3430-3439. [Google Scholar] [CrossRef] [PubMed]
[45] 武星颖, 鲍月宁, 魏娜. 西洛他唑联合阿司匹林治疗腔隙性脑梗死的临床效果[J]. 临床合理用药, 2024, 17(27): 40-42+46.
[46] 胡劲松, 曾晓谕, 莫之元. CYP2C19基因多态性与氯吡格雷治疗脑梗死效果的相关性[J]. 临床医学研究与实践, 2023, 8(22): 61-64.

为你推荐